Status In progress
Process STA 2018
ID number 1175

Provisional Schedule

Committee meeting: 1 14 February 2019
Expected publication 29 May 2019

Project Team

Project lead Kate Moore

Email enquiries


Companies sponsors AstraZeneca (durvalumab)
Others Department of Health
  NHS England
  Welsh Government
Patient carer groups Roy Castle Lung Cancer Foundation
Professional groups British Thoracic Oncology Group
  British Thoracic Society
  Cancer Research UK
  National Lung Cancer Forum for Nurses
  Royal College of Pathologists
  Royal College of Physicians
  Royal College of Radiologists


General commentators All Wales Therapeutic and Toxicology Centre
  British National Formulary
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Welsh Health Specialised Services Committee
Relevant research groups Institute of Cancer Research
  National Cancer Research Institute


Key events during the development of the guidance:

Date Update
09 May 2018 The company who produces durvalumab, AstraZeneca, has requested more time to compile an evidence submission for this technology. This delay means that this appraisal will be removed from the NICE’s reporting targets for timeliness. In addition, through this request for delay the company accepts that this drug will not be eligible to receive interim CDF funding from the date of marketing authorization. We will provide an updated evidence submission deadline in due course.
01 March 2018 Invitation to participate
06 September 2017 - 04 October 2017 Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators
26 June 2017 In progress, Topic referred
21 April 2017 Referral

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance